Berberine alkaloids as a treatment for chronic protozoally induced diarrhea
AssigneePRM Pharmaceuticals, Inc.
InventorJoseph T. McDevitt
Life of this patent
Estimating the term…
Abstract
A method for the treatment or prevention of chronic diarrhea caused by protozoa, especially microsporidia and cryptosporidia, in a patient is disclosed which method comprises administering to the patient an effective amount of a berberine alkaloid. The administration of the berberine alkaloid may be in combination with one or more antiprotozoal agents other than berberine.
Claims38
A method for the treatment or alleviation of symptoms of protozoally induced chronic diarrhea in a patient comprising administering to the patient an effective amount of a berberine alkaloid, and continuing the administration for a sufficient time to substantially alleviate the chronic diarrhea is induced by protozoa selected from the group consisting of Microsporridia spp. and Cryptospordia spp.
A composition for the treatment or alleviation of symptoms of chronic diarrhea induced by protozoa selected from the group consisting of Blastocystis hominis, Dientamoeba fragilis, Balantinium coli, Isopora belli, and Cylclospora cayetanensis, comprising a berberine alkaloid and a pharmaceutically acceptable carrier.
A composition for the treatment or alleviation of symptoms of protozoally induced chronic diarrhea in a patient comprising a berberine alkaloid selected from the group consisting of berberine and berberine hydrochloride, an antiprotozoal agent selected from the group consisting of albendazole and metronidazole, and a pharmaceutically acceptable carrier, wherein said diarrhea is induced by protozoa selected from the group consisting of Microsporidia spp. and Cryptosporidia spp.
A composition for the treatment or alleviation of symptoms of protozoally induced chronic diarrhea in a patient comprising a berberine alkaloid selected from the group consisting of berberrubine, coreximine, tetrahydropalmatine, jatrorrhizine, 13-hydroxyberberine chloride, coralyne chloride, 7,8-dihydro- 13-methylberberine, berberine acetone, 13-allylberberine, palmatine, and 13-benzylberberine;
- an antiprotozoal agent selected from the group consisting of albendazole and metronidazole;
- and a pharmaceutically acceptable carrier, wherein said diarrhea is induced by protozoa selected from the group consisting of Microsporidia spp. and Cryptosporidia spp.
A method for the treatment or alleviation of symptoms of protozoally induced chronic diarrhea in a patient comprising administering to the patient an effective amount of a berberine alkaloid, and continuing the administration for a sufficient time to substantially alleviate the chronic diarrhea is induced by protozoa selected from the group consisting of Blastocystis hominis, Dientamoeba fragilis Balantidium coli, Isoipora belli, and Cyclospora cayetanensis.
A composition for the treatment or alleviation of symptoms of protozoally induced chronic diarrhea induced by Microsporidia spp. or Cryptosporidia spp. in a patient comprising a berberine alkaloid selected from the group consisting of berberine and berberine hydrochloride and a pharmaceutically acceptable carrier.
A composition for the treatment or alleviation of symptoms of protozoally induced chronic diarrhea induced by Microsporidia spp. or Cryptosporidia spp. in a patient, comprising a berberine alkaloid selected from the group consisting of berberrubine, coreximine, tetrahydropalmatine, jatrorrhizine, 13-hydroxyberberine chloride, coralyne chloride, 7,8-dihydro- 13-methylberberine, berberine acetone, 13-allylberberine, palmatine, and 13-benzylberberine.
Dependencies are inferred from the claim text.